About Viamet Pharmaceuticals
Viamet Pharmaceuticals is a company based in Durham (United States) founded in 2005 by Thomas OHalloran was acquired by NovaQuest Capital Management in January 2018.. Viamet Pharmaceuticals has raised $160.8 million across 9 funding rounds from investors including Woodford Investment Management, U.S. Department of Defense and Brandon Point Industries. The company has 22 employees as of December 31, 2020. Viamet Pharmaceuticals offers products and services including Aivala.com, DevelopUniversity.com, Billionaires.University, FireProtectionConsultant.com, and Fescousa.com. Viamet Pharmaceuticals operates in a competitive market with competitors including Scynexis, F2g, Amplyx Pharmaceuticals, Biosergen and Elion Therapeutics, among others.
- Headquarter Durham, United States
- Employees 22 as on 31 Dec, 2020
- Founders Thomas OHalloran
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Mycovia Pharmaceuticals (Nc), Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$160.8 M (USD)
in 9 rounds
-
Latest Funding Round
$12 M (USD), Series E
Sep 28, 2016
-
Investors
Woodford Investment Management
& 8 more
-
Employee Count
22
as on Dec 31, 2020
-
Acquired by
NovaQuest Capital Management
(Jan 03, 2018)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Viamet Pharmaceuticals
Viamet Pharmaceuticals offers a comprehensive portfolio of products and services, including Aivala.com, DevelopUniversity.com, Billionaires.University, FireProtectionConsultant.com, and Fescousa.com. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Offers AI training to empower healthcare professionals for work and profit.
Provides online courses for skill development and education.
Delivers strategies for wealth-building and business acumen.
Offers fire safety consulting and training solutions.
Provides leading fire protection and emergency services.
Manages lodging and logistics for nuclear energy operations.
Advances satellite networks for global communications.
Delivers AI-driven content creation and copying tools.
Offers AI resources for enhancing business skills.
Funding Insights of Viamet Pharmaceuticals
Viamet Pharmaceuticals has successfully raised a total of $160.8M across 9 strategic funding rounds. The most recent funding activity was a Series E round of $12 million completed in September 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 9
- Last Round Series E — $12.0M
-
First Round
First Round
(26 Aug 2005)
- Investors Count 8
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep, 2016 | Amount | Series E - Viamet Pharmaceuticals | Valuation |
investors |
|
| Jun, 2015 | Amount | Grant - Viamet Pharmaceuticals | Valuation |
investors |
|
| Oct, 2014 | Amount | Series D - Viamet Pharmaceuticals | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Viamet Pharmaceuticals
Viamet Pharmaceuticals has secured backing from 9 investors, including institutional and venture fund investors. Prominent investors backing the company include Woodford Investment Management, U.S. Department of Defense and Brandon Point Industries. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Founded Year | Domain | Location | |
|
Investments are made in innovative life science companies globally.
|
Founded Year | Domain | Location | |
|
Early-stage life sciences investments are targeted in the healthcare sector.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Viamet Pharmaceuticals
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Viamet Pharmaceuticals
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Viamet Pharmaceuticals Comparisons
Competitors of Viamet Pharmaceuticals
Viamet Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Scynexis, F2g, Amplyx Pharmaceuticals, Biosergen and Elion Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developing glucan synthase inhibitors for the treatment of fungal infections.
|
|
| domain | founded_year | HQ Location |
Drugs for systemic fungal diseases are discovered and developed.
|
|
| domain | founded_year | HQ Location |
Broad-spectrum fungal enzyme inhibitors are developed by clinical-stage biopharma.
|
|
| domain | founded_year | HQ Location |
Anti-fungal therapeutics are developed against invasive fungal diseases.
|
|
| domain | founded_year | HQ Location |
Therapeutics for invasive fungal infections are developed by Elion Therapeutics.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics are developed for recurrent vulvovaginal candidiasis treatment.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Viamet Pharmaceuticals
Frequently Asked Questions about Viamet Pharmaceuticals
When was Viamet Pharmaceuticals founded?
Viamet Pharmaceuticals was founded in 2005.
Where is Viamet Pharmaceuticals located?
Viamet Pharmaceuticals is headquartered in Durham, United States. It is registered at Durham, North Carolina, United States.
Is Viamet Pharmaceuticals a funded company?
Viamet Pharmaceuticals is a funded company, having raised a total of $160.8M across 9 funding rounds to date. The company's 1st funding round was a Series D of $60M, raised on Aug 26, 2005.
How many employees does Viamet Pharmaceuticals have?
As of Dec 31, 2020, the latest employee count at Viamet Pharmaceuticals is 22.
What does Viamet Pharmaceuticals do?
Viamet Pharmaceuticals was founded in 2005 in Durham, United States, within the biotechnology sector. Small molecule inhibitors of metalloenzymes are identified through the Metallophile platform to address chronic and life-threatening fungal infections. The lead candidate, VT-1161, is advanced in Phase 2b trials for recurrent vulvovaginal candidiasis and onychomycosis. Preclinical efforts include VT-1129 for cryptococcal meningitis and VT-1598 for invasive fungal infections.
Who are the top competitors of Viamet Pharmaceuticals?
Viamet Pharmaceuticals's top competitors include Scynexis, F2g and Amplyx Pharmaceuticals.
What products or services does Viamet Pharmaceuticals offer?
Viamet Pharmaceuticals offers Aivala.com, DevelopUniversity.com, Billionaires.University, FireProtectionConsultant.com, and 5 more products and services.
Who are Viamet Pharmaceuticals's investors?
Viamet Pharmaceuticals has 9 investors. Key investors include Woodford Investment Management, U.S. Department of Defense, Brandon Point Industries, Novartis Venture Fund, and Lilly Ventures.